Platinum sponsor

Amgen
Amgen harnesses the best of biology and technology to make people’s lives easier, fuller and longer. We draw upon our deep knowledge of science to push beyond what’s known today. We are one of the world’s leading independent biotech companies – fighting the toughest diseases and helping millions of people globally. For more information, visit www.amgen.com and follow us on LinkedIn, Twitter, Instagram, Facebook, YouTube and TikTok.

 

Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Reimagine medicine with us: Visit us at https://www.novartis.com.

Gold sponsor

Janssen Pharmaceutical Companies of Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated and cured, treatments are smarter and less invasive and solutions are personal. For more information, visit our website.

Silver sponsor

Advicenne
Advicenne is dedicated to developing innovative, effective and safe treatments for people living with rare renal diseases who have very limited therapeutic options. Thanks to our expertise in reformulation and drug delivery, we are uniquely positioned to develop and make available innovative treatments for both children and adults. We are dedicated to improving patients’ daily health and life and are committed to tackle the challenge of high unmet medical needs. Sibnayal® (combination of Potassium citrate and Potassium bicarbonate) has received its Marketing Approval for distal renal tubular acidosis (dRTA) in EU and GB. Sibnayal® is approved for both the genetic and acquired form of dRTA.

Argenx
Argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker in the U.S., Japan, Israel, the EU, the UK, Canada and China. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Twitter, and Instagram.

GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Our R&D focus is on four therapeutic areas: infectious diseases, HIV, immunology/respiratory and oncology. We are working to unlock the science of the immune system to improve outcomes for people affected by immune-mediated conditions. We will be sharing and discussing the latest science and emerging evidence around immune-mediated conditions at the 16th international symposium Sjogren Disease 2024. Website

 

Supported by

 

 

Endorsed by